Genetic Profile Predicts Who Will Benefit From Wegovy

Certain genes may identify patients with obesity who are most likely to respond strongly to Novo Nordisk’s weight-loss drug Wegovy, researchers reported on Monday. The study, released at the Digestive Disease Week meeting in Washington, found a 95% likelihood that patients…

Read Full Article (External Site)